BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data

BioNTech SE (NASDAQ:BNTX) is simply a planetary biopharmaceutical institution pioneering caller investigative therapies for crab and infectious diseases.

On April 13, BofA raised its terms people connected BioNTech SE (NASDAQ:BNTX) from $128 to $130, portion maintaining a ‘Buy’ standing connected the shares. The revised people indicates an upside of astir 20% from the existent terms levels.

The determination comes aft BioNTech SE (NASDAQ:BNTX) reported affirmative Phase 2 results for T-Pam successful second-line and aboriginal HER2-expressing endometrial cancer. The expert steadfast recovered these results encouraging and noted that they enactment a imaginable archetypal support wrong BioNTech’s expanding oncology pipeline.

BioNTech SE (NASDAQ:BNTX) is targeting full revenues successful the scope of €2 cardinal to €2.3 cardinal for FY 2026, down from €2.9 cardinal successful 2025. The institution expects little gross from the COVID-19 vaccine it developed successful concern with Pfizer, driven by declines successful some the European and United States markets. Moreover, the YoY diminution comes from a deficiency of expected one-time revenues, specified arsenic payments from Pfizer’s opt-out of the shingles programme past year.

While we admit the imaginable of BNTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 8 Best Wind Power and Solar Stocks to Buy Right Now and 10 Best Affordable Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey connected Google News.